Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist

A novel clinical study design was used to evaluate the blockade of a selective short-acting μ-opioid agonist (remifentanil) in 24 opioid-experienced subjects. Samidorphan (3-carboxamido-4-hydroxynaltrexone) is a novel opioid modulator with μ-antagonist properties. Objective (pupil diameter) and subj...

Descripción completa

Detalles Bibliográficos
Autores principales: Shram, Megan J., Silverman, Bernard, Ehrich, Elliot, Sellers, Edward M., Turncliff, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415969/
https://www.ncbi.nlm.nih.gov/pubmed/25928699
http://dx.doi.org/10.1097/JCP.0000000000000320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415969/
https://www.ncbi.nlm.nih.gov/pubmed/25928699
http://dx.doi.org/10.1097/JCP.0000000000000320

Ejemplares similares